# CAR T-cell therapy advances in lymphoma > Live situation record from CLSTR: https://clstr.news/situations/car-t-cell-therapy-advances-in-lymphoma > Updated: 2026-08-03T12:18:27.000Z. Sources: 5. Developments: 2. In late July 2026, researchers reported three genetic variants that influence the safety and efficacy of CAR T‑cell therapy in aggressive lymphoma patients, linking STXBP2 to severe inflammatory toxicity, ADMT​SL3 to protection, and PTPN22 to stronger CAR T‑cell expansion. At the same time, clinicians debated the relative merits of bispecific antibodies versus CAR T therapy for relapsed/refractory follicular lymphoma, highlighting concerns over toxicity and treatment logistics. A week later, a pre‑clinical study from Spain identified CD70 as a marker of relapse risk in follicular lymphoma and engineered a dual‑target CAR T product (ARI‑0001) that attacks both CD19 and CD70. The new construct showed superior tumor control compared with single‑target CAR T cells, suggesting a next step toward more effective, personalized immunotherapy for the disease. Together, the snapshots trace a trajectory from understanding patient‑specific genetic factors and therapeutic trade‑offs to the development of novel dual‑target CAR T strategies aimed at improving outcomes in follicular lymphoma. ## Timeline ### 2026-08-03: Dual‑target CAR‑T therapy shows improved control of follicular lymphoma in pre‑clinical study A Spanish research team created a dual CD19‑CD70 CAR‑T therapy that better controls follicular lymphoma in pre‑clinical models, after identifying CD70 as a relapse marker. 5 sources. https://clstr.news/cluster/dualtarget-cart-therapy-shows-improved-control-of-follicular-lymphoma-in-preclinical-study ### 2026-07-22: CAR T-cell therapy advances and bispecific antibody debate in lymphoma care Research links three gene variants to CAR T‑cell therapy outcomes in lymphoma, while experts debate bispecific antibodies versus CAR T for follicular lymphoma treatment. 3 sources. https://clstr.news/cluster/car-t-cell-therapy-advances-and-bispecific-antibody-debate-in-lymphoma-care --- Cite as: CAR T-cell therapy advances in lymphoma. CLSTR, https://clstr.news/situations/car-t-cell-therapy-advances-in-lymphoma